Rhabdoid tumour predisposition syndrome
Zuletzt aktualisiert 18. Aug 2020
Erfüllt die redaktionelle Richtlinien
- HerunterladenHerunterladen
- Teilen
- Language
- Diskussion
- Audio-Version
- Zu bevorzugten Quellen bei Google hinzufügen
Rhabdoid tumour predisposition syndrome (RTPS) is characterised by a high risk of developing cancerous (malignant) growths called rhabdoid tumours. These highly aggressive tumours are called rhabdoid because their cells resemble rhabdomyoblasts, which are cells that are normally found in embryos before birth and develop into muscles used for movement (skeletal muscles).
Beschreibung
Rhabdoid tumour predisposition syndrome (RTPS) is characterised by a high risk of developing cancerous (malignant) growths called rhabdoid tumours. These highly aggressive tumours are called rhabdoid because their cells resemble rhabdomyoblasts, which are cells that are normally found in embryos before birth and develop into muscles used for movement (skeletal muscles).
Rhabdoid tumours are rare in the general population. They usually occur in the first year of life, and are much less likely to appear after age 4. In people with RTPS, the tumours occur at an average age of 4 to 7 months, and can even occur before birth. Affected individuals may have multifocal synchronous tumours, which means that multiple tumours that develop independently (primary tumours) occur at the same time. The rhabdoid tumours that occur in RTPS usually grow and spread more quickly than those in children without this predisposition, and affected individuals often do not survive past childhood.
More than half of all malignant rhabdoid tumours (MRTs) develop in the cerebellum, which is the part of the brain that coordinates movement. Rhabdoid tumours in the brain and spinal cord (central nervous system) are called atypical teratoid/rhabdoid tumours (AT/RTs).
Rhabdoid tumours also occur outside the central nervous system. These tumours include rhabdoid tumours of the kidneys (RTKs) and tumours that develop in other organs and tissues of the body (called extrarenal malignant rhabdoid tumours or eMRTs). The type of rhabdoid tumour can vary among individuals with RTPS, even within the same family.
Tumours other than rhabdoid tumours can also occur in people with RTPS. Some affected children develop noncancerous (benign) tumours called schwannomas, which grow on nerve cells. Women with RTPS are at increased risk of developing a rare type of ovarian cancer called small cell cancer of the ovary hypercalcemic type (SCCOHT).
Inheritance patterns
The source lists the following possible inheritance patterns: Autosomal dominant. More than one pattern can apply in different cases.
Related genes
Other names
Familial posterior fossa brain tumour of infancy
Familial posterior fossa brain tumour syndrome
Familial rhabdoid tumour
Hereditary SWI/SNF deficiency syndrome
Rhabdoid predisposition syndrome
RTPS
Related patient information and medicines
Patient information leaflet
Wilms-Tumor
A Wilms' tumour is a type of kidney cancer that usually affects young children. Wilms' tumours can appear in older children and adults but this is very rare. There are several other very rare types of kidney cancers that may occur in children. These include clear cell sarcoma of the kidney and malignant rhabdoid tumour of Arztpraxis kidney. Kongenital.
Patient information leaflet
Sjögren-Syndrom
Sjögren's syndrome is an autoimmune disease that causes the glands that produce tears and saliva to stop working. It is a life-long condition but treatments can help control symptoms such as dry eyes and dry mouth. What is Sjögren's syndrome. It can also affect other organs including the lungs, kidneys, skin and the nervous system. Sjögren's.
Patient information leaflet
Gehirntumore
This leaflet aims to give a brief overview of the various types of brain tumours. The treatment and survival rates vary greatly, depending on factors such as the type of tumour and the location in the brain. Understanding the brain The main parts of the brain include: The cerebrum. The next layer is called the arachnoid. Under the arachnoid tissue.
Patient information leaflet
Karpaltunnelsyndrom
Karpaltunnelsyndrom is a set of symptoms thought to be caused by squashing (compression) of the median nerve in the carpal tunnel. What is carpal tunnel syndrome. This syndrome is a set of symptoms thought to be caused by squas... Obesity . Pregnancy. Osteoarthritis of Arztpraxis joint at the base of the thumb (metacarpophalangeal joint). This is due.
Patient information leaflet
Refeeding-Syndrom
Refeeding-Syndrom was first described in Far East prisoners after the second world war when they developed Herzversagen after starting to eat again after a prolonged period of starvation. What is refeeding syndrome. Refeeding-Syndrom is a dangerous and life threatening shift of fluids and body salts (electrolytes) that can occur when.
Patient information leaflet
Cushing-Syndrom
Cushing-Syndrom is caused by too high a level of glucocorticoid in the body. This can be caused by taking steroid medication long-term (the common cause) or by the body making too much cortisol (the main glucocorticoid made by the body). There are v... The most common cause of excess cortisol is a small, non-cancerous tumour in the pituitary.
Weiterführende Lektüre und Referenzen
- Rhabdoid tumour predisposition syndrome; MedlinePlus, National Library of Medicine.
- Agaimy A, Foulkes WD. Hereditary SWI/SNF complex deficiency syndromes. Semin Diagn Pathol. 2018 May;35(3):193-198. doi: 10.1053/j.semdp.2018.01.002. Epub 2018 Feb 1.
- Eaton KW, Tooke LS, Wainwright LM, Judkins AR, Biegel JA. Spectrum of SMARCB1/INI1 mutations in familial and sporadic rhabdoid tumors. Pediatr Blood Cancer. 2011 Jan;56(1):7-15. doi: 10.1002/pbc.22831.
- Gigante L, Paganini I, Frontali M, Ciabattoni S, Sangiuolo FC, Papi L. Rhabdoid tumor predisposition syndrome caused by SMARCB1 constitutional deletion: prenatal detection of new case of recurrence in siblings due to gonadal mosaicism. Fam Cancer. 2016 Jan;15(1):123-6. doi: 10.1007/s10689-015-9836-6.
- Hulsebos TJ, Kenter S, Verhagen WI, Baas F, Flucke U, Wesseling P. Premature termination of SMARCB1 translation may be followed by reinitiation in schwannomatosis-associated schwannomas, but results in absence of SMARCB1 expression in rhabdoid tumors. Acta Neuropathol. 2014 Sep;128(3):439-48. doi: 10.1007/s00401-014-1281-3. Epub 2014 Apr 17.
- Kim KH, Roberts CW. Mechanisms by which SMARCB1 loss drives rhabdoid tumor growth. Cancer Genet. 2014 Sep;207(9):365-72. doi: 10.1016/j.cancergen.2014.04.004. Epub 2014 Apr 13.
- Kordes U, Bartelheim K, Modena P, Massimino M, Biassoni V, Reinhard H, Hasselblatt M, Schneppenheim R, Fruhwald MC. Favorable outcome of patients affected by rhabdoid tumors due to rhabdoid tumor predisposition syndrome (RTPS). Pediatr Blood Cancer. 2014 May;61(5):919-21. doi: 10.1002/pbc.24793. Epub 2013 Oct 3.
- Medina PP, Sanchez-Cespedes M. Involvement of the chromatin-remodeling factor BRG1/SMARCA4 in human cancer. Epigenetics. 2008 Mar-Apr;3(2):64-8. doi: 10.4161/epi.3.2.6153. Epub 2008 Apr 17.
- Schneppenheim R, Fruhwald MC, Gesk S, Hasselblatt M, Jeibmann A, Kordes U, Kreuz M, Leuschner I, Martin Subero JI, Obser T, Oyen F, Vater I, Siebert R. Germline nonsense mutation and somatic inactivation of SMARCA4/BRG1 in a family with rhabdoid tumor predisposition syndrome. Am J Hum Genet. 2010 Feb 12;86(2):279-84. doi: 10.1016/j.ajhg.2010.01.013. Epub 2010 Feb 4.
- Sredni ST, Tomita T. Rhabdoid tumor predisposition syndrome. Pediatr Dev Pathol. 2015 Jan-Feb;18(1):49-58. doi: 10.2350/14-07-1531-MISC.1. Epub 2014 Dec 10.
Artikelverlauf
Artikel auch verfügbar in Englisch, Deutsch, Spanisch, Französisch, Italienisch, Portugiesisch, Hindi, Hebräisch, Arabisch, und Schwedisch.
18. Aug 2020 | Neueste Version
1 Apr 2018 | Ursprünglich veröffentlicht
Nehmen Sie an der Diskussion teil
Teilen Sie Ihre Gedanken oder Erfahrungen mit anderen in unserem Patientengemeinschaften.
Fragen, teilen, verbinden.
Durchsuchen Sie Diskussionen, stellen Sie Fragen und teilen Sie Erfahrungen zu Hunderten von Gesundheitsthemen.
Abonnieren Sie den Patienten-Newsletter
Ihre wöchentliche Dosis klarer, vertrauenswürdiger Gesundheitsberatung - geschrieben, um Ihnen zu helfen, sich informiert, selbstbewusst und in Kontrolle zu fühlen.
Durch das Abonnieren akzeptieren Sie unsere Datenschutzrichtlinie. Sie können sich jederzeit abmelden. Wir verkaufen Ihre Daten niemals.